Short Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Rises By 62.2%

Monopar Therapeutics Inc. (NASDAQ:MNPR) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totaling 822,858 shares, an increase of 62.2% from the November 30th total of 507,439 shares. Based on an average trading volume of 181,013 shares, the short-interest ratio is presently 4.5 days. Currently, 15.5% of the company’s stock are short sold. Currently, 15.5% of the company’s stock are short sold. Based on an average trading volume of 181,013 shares, the short-interest ratio is presently 4.5 days.

Monopar Therapeutics Stock Up 0.8%

Monopar Therapeutics stock traded up $0.53 during trading hours on Tuesday, hitting $66.10. The stock had a trading volume of 505,364 shares, compared to its average volume of 73,785. The company has a 50-day moving average of $79.24 and a two-hundred day moving average of $60.49. Monopar Therapeutics has a fifty-two week low of $21.00 and a fifty-two week high of $105.00. The company has a market cap of $441.53 million, a PE ratio of -19.20 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). As a group, analysts forecast that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Transactions at Monopar Therapeutics

In other news, CFO Quan Anh Vu acquired 1,500 shares of Monopar Therapeutics stock in a transaction that occurred on Friday, December 26th. The stock was purchased at an average price of $69.95 per share, with a total value of $104,925.00. Following the completion of the transaction, the chief financial officer owned 1,500 shares in the company, valued at approximately $104,925. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 20.50% of the company’s stock.

Institutional Trading of Monopar Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics in the third quarter worth about $28,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Monopar Therapeutics in the 2nd quarter valued at approximately $34,000. AlphaQuest LLC acquired a new position in shares of Monopar Therapeutics in the 1st quarter worth approximately $44,000. BNP Paribas Financial Markets lifted its position in shares of Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after buying an additional 349 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after buying an additional 1,821 shares during the period. Institutional investors own 1.83% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on MNPR. Wall Street Zen raised Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. Raymond James Financial lowered Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and reduced their target price for the stock from $142.00 to $123.00 in a report on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Wednesday, October 8th. Lake Street Capital initiated coverage on shares of Monopar Therapeutics in a research report on Tuesday, September 23rd. They issued a “buy” rating and a $106.00 price target on the stock. Finally, Leerink Partners began coverage on shares of Monopar Therapeutics in a report on Monday, November 10th. They set an “outperform” rating and a $115.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $106.20.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.